C-peptide vs ACE-031
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and ACE-031 (ACE-031 (soluble activin receptor type IIB-Fc)) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | ACE-031 |
|---|---|---|
| Category | Pain Management | Muscle & Performance |
| Full Name | Connecting peptide (C-peptide) | ACE-031 (soluble activin receptor type IIB-Fc) |
| Molecular Weight | 3020.3 Da | ~95 kDa |
| Half-Life | ~20-30 min | Days to weeks |
| Amino Acids | 31 | N/A |
| Typical Dose | no approved analgesic dose|research-only | 0.1-3 mg/kg in early studies |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 75 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
ACE-031 Benefits
- ✓myostatin/activin neutralization
- ✓lean mass gain
- ✓muscle function support
- ✓anti-catabolic effect
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
ACE-031 Dosing
Clinical studies used single or repeated SC doses|dose escalation in mg/kg|monitoring for edema/bleeding
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
ACE-031 Side Effects
- ⚠telangiectasia/vascular effects
- ⚠epistaxis
- ⚠headache/edema
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
ACE-031
ACE-031 produced increases in lean mass in early studies, but development was curtailed after safety concerns and variable efficacy. Its literature remains important because it validated activin receptor blockade as a muscle-building strategy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.